Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept
Open Access
- 8 December 2022
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (12), 2754
- https://doi.org/10.3390/pharmaceutics14122754
Abstract
Alpha-1 antitrypsin (AAT) deficiency is a genetic disorder associated with pulmonary emphysema and bronchiectasis. Its management currently consists of weekly infusions of plasma-purified human AAT, which poses several issues regarding plasma supplies, possible pathogen transmission, purification costs, and parenteral administration. Here, we investigated an alternative administration strategy for augmentation therapy by combining recombinant expression of AAT in bacteria and the production of a respirable powder by spray drying. The same formulation approach was then applied to plasma-derived AAT for comparison. Purified, active, and endotoxin-free recombinant AAT was produced at high yields and formulated using L-leucine and mannitol as excipients after identifying compromise conditions for protein activity and good aerodynamic performances. An oxygen-free atmosphere, both during formulation and powder storage, slowed down methionine-specific oxidation and AAT inactivation. This work is the first peer-reviewed report of AAT formulated as a dry powder, which could represent an alternative to current treatments.Funding Information
- Regione Emilia Romagna POR-FESR (PG/2015/731196)
This publication has 62 references indexed in Scilit:
- The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromoleculesEuropean Journal of Pharmaceutics and Biopharmaceutics, 2013
- Effects of glycosylation on the stability and flexibility of a metastable protein: The human serpin α1-antitrypsinInternational Journal of Mass Spectrometry, 2011
- Biochemical, molecular characterization, and glycoproteomic analyses of α1‐proteinase inhibitor products used for replacement therapy*Transfusion, 2006
- Neutrophil serine proteases: specific regulators of inflammationNature Reviews Immunology, 2006
- Recombinant human alpha-1 proteinase inhibitor: towards therapeutic useAmino Acids, 2006
- A pilot study comparing the purity, functionality and isoform composition of alpha-1-proteinase inhibitor (human) productsCurrent Medical Research and Opinion, 2005
- 1-Antitrypsin deficiency * 4: Molecular pathophysiologyThorax, 2004
- Oxidation of either methionine super351 or methionine super358 in alpha 1-antitrypsin causes loss of anti-neutrophil elastase activityOnline Journal of Public Health Informatics, 2000
- Effects of glycosylation on the folding and stability of human, recombinant and cleaved α1-antitrypsinJournal of Molecular Biology, 1992
- The synthesis and analytical use of a highly sensitive and convenient substrate of elastaseBiochemical Medicine, 1974